Ser83
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser83  -  TAGLN2 (human)

Site Information
PVkkIQAstMAFkQM   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 19083400

In vivo Characterization
Methods used to characterize site in vivo:
2D analysis ( 1 ) , immunoprecipitation ( 1 ) , mass spectrometry ( 1 , 2 ) , mutation of modification site ( 1 )
Disease tissue studied:
liver cancer ( 1 ) , hepatocellular carcinoma ( 1 )
Relevant cell line - cell type - tissue:
HCC (hepatic) ( 1 ) , HeLa (cervical) ( 2 ) , Hep 3B2.1-7 (hepatic) ( 1 )

Upstream Regulation
Putative in vivo kinases:
CDK14 (human) ( 1 )
Treatments:
siRNA ( 1 )

Downstream Regulation
Effects of modification on TAGLN2:
molecular association, regulation ( 1 )
Effects of modification on biological processes:
carcinogenesis, induced ( 1 ) , cell motility, induced ( 1 ) , cytoskeletal reorganization ( 1 )
Inhibit interaction with:
ACTB (human) ( 1 )

References 

1

Leung WK, et al. (2011) A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility. Oncogene 30, 4464-75
21577206   Curated Info

2

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info